Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer
Phase I/II Study of Increasing Doses of Lutetium-177 Labeled Chimeric Monoclonal Antibody cG250 (177^Lu-DOTA-cG250) in Patients With Advanced Renal Cancer
Sponsor: Ludwig Institute for Cancer Research
Listed as NCT00142415, this PHASE1/PHASE2 trial focuses on Metastatic Renal Cell Carcinoma and remains completed. Sponsored by Ludwig Institute for Cancer Research, it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Mar 2022 — Nov 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
May 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — May 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ludwig Institute for Cancer Research
- Radboud University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Nijmegen, Netherlands